A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress
- 28 May 2009
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (7) , 709-714
Abstract
Aim: To assess the effect of three times daily mealtime inhaled insulin therapy compared with once daily basal insulin glargine therapy on 72‐h glucose profiles, glucose variability and oxidative stress in type 2 diabetes patients. Methods: In an inpatient crossover study, 40 subjects with type 2 diabetes were randomized to receive 9 days of inhaled insulin three times daily before meals or 9 days of glargine administered in the morning before breakfast in a randomized order. During the last 72 h in each phase, glucose was measured with continuous glucose monitoring. Activation of oxidative stress was measured by determining the 15( S )‐8‐iso‐PGF 2α ‐secretion in 24‐h urine samples. Results: Inhaled insulin improved overall and postprandial glucose control significantly better than insulin glargine (p < 0.0001). There was a trend towards a greater reduction in glucose variability (8–9%) in the inhaled group [p = 0.1430 and p = 0.3298 for mean amplitude of glycaemic excursions (MAGEs) and mean of daily differences respectively]. Oxidative stress, estimated by determining the urinary isoprostane excretion (15( S )‐8‐iso‐PGF 2α ), was equally reduced from baseline by both treatments. No correlation was found between glucose variability and oxidative stress in both groups. Conclusions: This study showed a mealtime insulin approach to improve glycaemic control more than a basal insulin approach. These findings indicate also that lowering glucose using insulin treatment lowers oxidative stress over time, at least for the study period of 9 days, in type 2 diabetes patients. Contrary to earlier data, we found no correlation between glucose variability (MAGE) and oxidative stress (15( S )‐8‐iso‐PGF 2α ) in this study.Keywords
This publication has 17 references indexed in Scilit:
- Glycemic Exposure Is Affected Favorably by Inhaled Human Insulin (Exubera) as Compared with Subcutaneous Insulin Glargine (Lantus) in Patients with Type 2 DiabetesDiabetes Technology & Therapeutics, 2009
- Glucose variability, blood pressure and arterial stiffness in type 1 diabetesDiabetes Research and Clinical Practice, 2008
- Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic PatientsDiabetes, 2008
- Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trialThe Lancet, 2008
- Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stressPediatric Diabetes, 2008
- A Novel Analytical Method for Assessing Glucose Variability: Using CGMS in Type 1 Diabetes MellitusDiabetes Technology & Therapeutics, 2006
- Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapyJournal of Diabetes and its Complications, 2006
- Should minimal blood glucose variability become the gold standard of glycemic control?Journal of Diabetes and its Complications, 2005
- A Novel Approach to Continuous Glucose Analysis Utilizing Glycemic VariationDiabetes Technology & Therapeutics, 2005
- Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instabilityDiabetologia, 1972